MENU
+Compare
BMY
Stock ticker: NYSE
AS OF
Nov 13, 04:59 PM (EDT)
Price
$48.64
Change
-$0.44 (-0.90%)
Capitalization
99.91B

BMY stock forecast, quote, news & analysis

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders... Show more

BMY
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. BMY showed earnings on October 30, 2025. You can read more about the earnings report here.
Interact to see
Advertisement
A.I.Advisor
a Summary for BMY with price predictions
Nov 12, 2025

BMY in upward trend: 10-day moving average moved above 50-day moving average on November 07, 2025

The 10-day moving average for BMY crossed bullishly above the 50-day moving average on November 07, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 30, 2025. You may want to consider a long position or call options on BMY as a result. In of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for BMY just turned positive on October 30, 2025. Looking at past instances where BMY's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

BMY moved above its 50-day moving average on October 30, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BMY advanced for three days, in of 306 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

BMY broke above its upper Bollinger Band on October 30, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for BMY entered a downward trend on November 07, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.385) is normal, around the industry mean (9.612). P/E Ratio (16.525) is within average values for comparable stocks, (23.835). Projected Growth (PEG Ratio) (1.120) is also within normal values, averaging (2.037). BMY has a moderately high Dividend Yield (0.051) as compared to the industry average of (0.028). P/S Ratio (2.081) is also within normal values, averaging (3.560).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BMY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 76, placing this stock worse than average.

A.I.Advisor
published Dividends

BMY paid dividends on November 03, 2025

Bristol-Myers Squibb Co BMY Stock Dividends
А dividend of $0.62 per share was paid with a record date of November 03, 2025, and an ex-dividend date of October 03, 2025. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Merck & Co (NYSE:MRK), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 98.13B. The market cap for tickers in the group ranges from 72.83K to 910.93B. LLY holds the highest valuation in this group at 910.93B. The lowest valued company is CRXTQ at 72.83K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was 3%. For the same Industry, the average monthly price growth was 1%, and the average quarterly price growth was 19%. OGN experienced the highest price growth at 21%, while GIKLY experienced the biggest fall at -10%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was -9%. For the same stocks of the Industry, the average monthly volume growth was 72% and the average quarterly volume growth was 42%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 31
P/E Growth Rating: 63
Price Growth Rating: 51
SMR Rating: 62
Profit Risk Rating: 76
Seasonality Score: 4 (-100 ... +100)
View a ticker or compare two or three
BMY
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a manufacturer of pharmaceuticals products

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
Route 206 and Province Line Road
Phone
+1 609 252-4621
Employees
34100
Web
https://www.bms.com